Why Geron Stock Is Falling Today
Portfolio Pulse from Erica Kollmann
Geron Corporation's (NASDAQ:GERN) stock is declining due to FDA staff raising safety concerns over its anemia drug, imetelstat. The FDA questioned the clinical meaningfulness of the data and noted a high rate of low red blood cell counts. Despite this, Geron has an average 1-year price target of $4, indicating a potential upside of 111.08%, with 3 analysts holding bullish ratings.

March 12, 2024 | 6:43 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Geron Corporation's stock is falling after FDA staff raised safety concerns over its anemia drug, imetelstat, questioning the clinical meaningfulness of the data and noting a high rate of low red blood cell counts.
The FDA's safety concerns directly impact Geron's potential revenue and market trust in its leading drug, imetelstat. This negative sentiment is likely to affect the stock's short-term performance negatively, as evidenced by the significant drop in stock price and high trading volume. However, the bullish analyst ratings and significant potential upside suggest that the long-term outlook might still be positive, depending on how Geron addresses these concerns.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100